Staub Daniel, Partovi Sasan, Zeller Thomas, Breidthardt Tobias, Kaech Max, Boeddinghaus Jasper, Puelacher Christian, Nestelberger Thomas, Aschwanden Markus, Mueller Christian
1 Department of Angiology, University Hospital Basel, CH-4031 Basel, Switzerland ; 2 Department of Radiology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio, USA ; 3 Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany ; 4 Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, Basel, Switzerland.
Cardiovasc Diagn Ther. 2016 Jun;6(3):221-33. doi: 10.21037/cdt.2016.03.01.
Identifying patients likely to have improved renal function after percutaneous transluminal renal angioplasty and stenting (PTRA) for renal artery stenosis (RAS) is challenging. The purpose of this study was to use a comprehensive multimarker assessment to identify those patients who would benefit most from correction of RAS.
In 127 patients with RAS and decreased renal function and/or hypertension referred for PTRA, quantification of hemodynamic cardiac stress using B-type natriuretic peptide (BNP), renal function using estimated glomerular filtration rate (eGFR), parenchymal renal damage using resistance index (RI), and systemic inflammation using C-reactive protein (CRP) were performed before intervention.
Predefined renal function improvement (increase in eGFR ≥10%) at 6 months occurred in 37% of patients. Prognostic accuracy as quantified by the area under the receiver-operating characteristics curve for the ability of BNP, eGFR, RI and CRP to predict renal function improvement were 0.59 (95% CI, 0.48-0.70), 0.71 (95% CI, 0.61-0.81), 0.52 (95% CI, 0.41-0.65), and 0.56 (95% CI, 0.44-0.68), respectively. None of the possible combinations increased the accuracy provided by eGFR (lower eGFR indicated a higher likelihood for eGFR improvement after PTRA, P=ns for all). In the subgroup of 56 patients with pre-interventional eGFR <60 mL/min/1.73 m(2), similar findings were obtained.
Quantification of renal function, but not any other pathophysiologic signal, provides at least moderate accuracy in the identification of patients with RAS in whom PTRA will improve renal function.
对于因肾动脉狭窄(RAS)而行经皮腔内肾血管成形术和支架置入术(PTRA)的患者,识别哪些患者肾功能可能改善具有挑战性。本研究的目的是使用全面的多标志物评估来识别那些将从纠正RAS中获益最大的患者。
在127例因RAS且肾功能下降和/或高血压而转诊接受PTRA的患者中,在干预前使用B型利钠肽(BNP)对血流动力学心脏应激进行量化,使用估计肾小球滤过率(eGFR)评估肾功能,使用阻力指数(RI)评估肾实质损伤,使用C反应蛋白(CRP)评估全身炎症。
6个月时预定义的肾功能改善(eGFR增加≥10%)发生在37%的患者中。BNP、eGFR、RI和CRP预测肾功能改善能力的受试者操作特征曲线下面积所量化的预后准确性分别为0.59(95%CI,0.48 - 0.70)、0.71(95%CI,0.61 - 0.81)、0.52(95%CI,0.41 - 0.65)和0.56(95%CI,0.44 - 0.68)。没有任何一种可能的组合能提高eGFR所提供的准确性(较低的eGFR表明PTRA后eGFR改善的可能性更高,所有P值均无统计学意义)。在干预前eGFR<60 mL/min/1.73 m²的56例患者亚组中,获得了类似的结果。
肾功能的量化而非任何其他病理生理信号,在识别PTRA可改善肾功能的RAS患者中至少提供了中等程度的准确性。